Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
Hong Kong · Delayed Price · Currency is HKD 7.57
-0.51 (-6.31%)
Aug 5, 2025, 4:08 PM HKT
Accolade Revenue
In the year 2024, Jiangsu Recbio Technology had annual revenue of 27.01M CNY, down -11.10%. Jiangsu Recbio Technology had revenue of 9.39M in the half year ending December 31, 2024, with 179.57% growth.
Revenue
27.01M CNY
Revenue Growth
-11.10%
P/S Ratio
128.91
Revenue / Employee
50.86K CNY
Employees
531
Market Cap
3.70B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.01M | -3.37M | -11.10% |
| Dec 31, 2023 | 30.38M | 25.05M | 470.46% |
| Dec 31, 2022 | 5.33M | -874.00K | -14.10% |
| Dec 31, 2021 | 6.20M | 4.74M | 325.17% |
| Dec 31, 2020 | 1.46M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |